- Home
- OABI vs SABA Comparison
OABI vs SABA Comparison
Compare OABI & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- SABA
- Stock Information
- Founded
- OABI 2012
- SABA 1988
- Country
- OABI United States
- SABA United States
- Employees
- OABI N/A
- SABA N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- OABI Health Care
- SABA
- Exchange
- OABI Nasdaq
- SABA Nasdaq
- Market Cap
- OABI 307.4M
- SABA 247.3M
- IPO Year
- OABI N/A
- SABA N/A
- Fundamental
- Price
- OABI $2.28
- SABA $8.68
- Analyst Decision
- OABI Strong Buy
- SABA
- Analyst Count
- OABI 3
- SABA 0
- Target Price
- OABI $7.00
- SABA N/A
- AVG Volume (30 Days)
- OABI 780.2K
- SABA 290.0K
- Earning Date
- OABI 03-18-2025
- SABA 01-01-0001
- Dividend Yield
- OABI N/A
- SABA 12.91%
- EPS Growth
- OABI N/A
- SABA N/A
- EPS
- OABI N/A
- SABA N/A
- Revenue
- OABI $26,391,000.00
- SABA N/A
- Revenue This Year
- OABI $77.72
- SABA N/A
- Revenue Next Year
- OABI $30.95
- SABA N/A
- P/E Ratio
- OABI N/A
- SABA N/A
- Revenue Growth
- OABI N/A
- SABA N/A
- 52 Week Low
- OABI $2.23
- SABA $3.64
- 52 Week High
- OABI $5.54
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- OABI 27.98
- SABA 35.58
- Support Level
- OABI $2.38
- SABA $8.66
- Resistance Level
- OABI $2.57
- SABA $8.98
- Average True Range (ATR)
- OABI 0.18
- SABA 0.11
- MACD
- OABI -0.04
- SABA 0.01
- Stochastic Oscillator
- OABI 4.42
- SABA 21.43
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.